dc.creator | Anastasilakis, A. D. | en |
dc.creator | Goulis, D. G. | en |
dc.creator | Polyzos, S. A. | en |
dc.creator | Gerou, S. | en |
dc.creator | Koukoulis, G. N. | en |
dc.creator | Efstathiadou, Z. | en |
dc.creator | Kita, M. | en |
dc.creator | Avramidis, A. | en |
dc.date.accessioned | 2015-11-23T10:22:11Z | |
dc.date.available | 2015-11-23T10:22:11Z | |
dc.date.issued | 2008 | |
dc.identifier | 10.1111/j.1742-1241.2008.01768.x | |
dc.identifier.issn | 1368-5031 | |
dc.identifier.uri | http://hdl.handle.net/11615/25537 | |
dc.description.abstract | Aims: We aimed to compare the effect of risedronate (RIS) and teriparatide (TPTD) (recombinant human parathyroid hormone 1-34) on bone turnover markers in women with postmenopausal osteoporosis. Methods: Forty-four Caucasian women (age 65.1 +/- 1.6 years) with postmenopausal osteoporosis were randomly assigned to receive either RIS 35 mg once weekly (n = 22) or TPTD 20 mu g once daily (n = 22) for 12 months. Serum N-terminal propeptide of type 1 collagen (P1NP), C-terminal telopeptide of type 1 collagen (CTx), total alkaline phosphatase (ALP) and intact parathyroid hormone (iPTH) were obtained from all women before, 3 and 6 months after treatment initiation. Lumbar spine bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry before and 12 months after treatment initiation. Results: P1NP, CTx and total ALP levels decreased in RIS group (p < 0.001) and increased in TPTD group (p < 0.001) throughout the treatment. iPTH increased significantly in RIS group (p < 0.05) and decreased in TPTD group (p < 0.001). Finally, lumbar spine BMD increased significantly in both RIS (p = 0.003) and TPTD groups (p < 0.001) without significant differences between them. Conclusions: Our data suggest that both serum P1NP and CTx are reliable markers of RIS and TPTD action in women with postmenopausal osteoporosis. In a similar way, serum total ALP can be used as an alternative marker for monitoring both RIS and TPTD action, while iPTH can be used only for TPTD-treated women. The increase in P1NP and CTx after 3 months of treatment with RIS or TPTD can predict the increase in BMD after 12 months of treatment. | en |
dc.source | International Journal of Clinical Practice | en |
dc.source.uri | <Go to ISI>://WOS:000255832800016 | |
dc.subject | PARATHYROID-HORMONE (1-34) | en |
dc.subject | ALENDRONATE THERAPY | en |
dc.subject | MINERAL DENSITY | en |
dc.subject | RESORPTION | en |
dc.subject | PERSISTENCE | en |
dc.subject | COLLAGEN | en |
dc.subject | FRACTURE | en |
dc.subject | BISPHOSPHONATES | en |
dc.subject | COMBINATION | en |
dc.subject | PHOSPHATASE | en |
dc.subject | Medicine, General & Internal | en |
dc.subject | Pharmacology & Pharmacy | en |
dc.title | Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial | en |
dc.type | journalArticle | en |